The drug Lyxumia is used in diabetes mellitus type 2 in adults to achieve glycemic control in patients, or in diabetes mellitus that is not controlled by hypoglycemic therapy.
Lixisenatide slows gastric emptying, thereby reducing the rate of increase in blood glucose concentration after meals. The effect on gastric emptying may also contribute to weight loss.
Lixisenatide is a potent and selective agonist of the glucagon-like peptide-1 (GLP-1) receptor. The GLP-1 receptor is the target of native GLP-1, an endogenous hormone of internal secretion that potentiates glucose-dependent insulin secretion by beta cells of the pancreatic islets. The action of lixisenatide is associated with its specific interaction with GLP-1 receptors, leading to an increase in the intracellular content of cyclic adenosine monophosphate (cAMP). Lixisenatide stimulates insulin secretion by beta cells of the pancreatic islets in response to hyperglycemia. When blood glucose levels drop to normal, stimulation of insulin secretion ceases, reducing the risk of hypoglycemia. In hyperglycemia, lixisenatide simultaneously suppresses glucagon secretion, but the protective reaction of glucagon secretion in response to hypoglycemia is maintained.
When administered (subcutaneously) once daily to patients with type 2 diabetes, lixisenatide improves glycemic control due to a rapid and prolonged reduction in blood glucose concentration after meals and on an empty stomach.
Active ingredient: Lixisenatide
Prescription drug
The drug is delivered from Germany.
